Diagnostic biologique de l'infection à Sars-CoV-2: stratégies et interprétation des résultats
S Hantz - Revue Francophone des Laboratoires, 2020 - Elsevier
Pour faire face à l’émergence du Sars-CoV-2 responsable d’une pandémie mondiale, de très
nombreux tests diagnostiques ont été développés et mis sur le marché dans un délai très …
nombreux tests diagnostiques ont été développés et mis sur le marché dans un délai très …
Papillomavirus: les virus et la physiopathologie de l'infection
S Alain, S Hantz, F Denis - Médecine thérapeutique/pédiatrie, 2010 - jle.com
Les papillomavirus constituent une vaste famille de plus de 200 petits virus à ADN non
enveloppés, capables d’infecter l’Homme et de nombreux mammifères, avec une spécificité d’…
enveloppés, capables d’infecter l’Homme et de nombreux mammifères, avec une spécificité d’…
[HTML][HTML] Humoral response after SARS-CoV-2 mRNA vaccination in a cohort of hemodialysis patients and kidney transplant recipients
C Danthu, S Hantz, A Dahlem, M Duval… - Journal of the …, 2021 - journals.lww.com
Background Kidney transplant recipients and patients receiving hemodialysis are
immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded …
immunocompromised populations that are prioritized for COVID-19 vaccination but were excluded …
Drug-resistant cytomegalovirus in transplant recipients: a French cohort study
S Hantz, F Garnier-Geoffroy… - Journal of …, 2010 - academic.oup.com
Objectives Cytomegalovirus (CMV) drug resistance is a therapeutic challenge in the transplant
setting. No longitudinal cohort studies of CMV resistance in a real-life setting have been …
setting. No longitudinal cohort studies of CMV resistance in a real-life setting have been …
Eight flavonoids and their potential as inhibitors of human cytomegalovirus replication
S Cotin, CA Calliste, MC Mazeron, S Hantz, JL Duroux… - Antiviral research, 2012 - Elsevier
The drugs currently available for treatment of severe human cytomegalovirus (HCMV)
infections suffer from many drawbacks, particularly toxicity, and potential teratogenicity …
infections suffer from many drawbacks, particularly toxicity, and potential teratogenicity …
Development of a standardized real time PCR for Torque teno viruses (TTV) viral load detection and quantification: A new tool for immune monitoring
…, M Dubé, M Joannes, M Essig, S Hantz… - Journal of Clinical …, 2018 - Elsevier
Background Torque teno viruses (TTV) are small DNA viruses whose replication is closely
linked to immune status. A growing number of publications underlined the potential of TTV …
linked to immune status. A growing number of publications underlined the potential of TTV …
Diagnostic des infections à papillomavirus: état des lieux et perspectives
S Hantz, S Alain, F Denis - Médecine thérapeutique/Pédiatrie, 2010 - jle.com
Les infections à papillomavirus humains sont associées à un grand polymorphisme clinique,
allant de lésions bénignes à malignes avec une distribution cutanée ou muqueuse. …
allant de lésions bénignes à malignes avec une distribution cutanée ou muqueuse. …
[HTML][HTML] Anti-CMV therapy, what next? A systematic review
C Gourin, S Alain, S Hantz - Frontiers in Microbiology, 2023 - frontiersin.org
Human cytomegalovirus (HCMV) is one of the main causes of serious complications in
immunocompromised patients and after congenital infection. There are currently drugs available …
immunocompromised patients and after congenital infection. There are currently drugs available …
Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity
G Champier, A Couvreux, S Hantz, A Rametti… - Antiviral …, 2008 - journals.sagepub.com
Background Benzimidazole d-ribonucleosides inhibit DNA packaging during human
cytomegalovirus (HCMV) replication. Although they have been shown to target pUL56 and pUL89 (…
cytomegalovirus (HCMV) replication. Although they have been shown to target pUL56 and pUL89 (…
First clinical description of letermovir resistance mutation in cytomegalovirus UL51 gene and potential impact on the terminase complex structure
…, I Garrigue, Q Lepiller, A Mirand, E Sidorov, S Hantz… - Antiviral Research, 2022 - Elsevier
Background Letermovir (LMV) is a human cytomegalovirus (HCMV) terminase inhibitor indicated
as prophylaxis for HCMV-positive stem-cell recipients. Its mechanism of action involves …
as prophylaxis for HCMV-positive stem-cell recipients. Its mechanism of action involves …
